Mediators of Inflammation

Mediators of Inflammation / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 9294018 |

Gabor J. Szebeni, Csaba Vizler, Klara Kitajka, Laszlo G. Puskas, "Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters", Mediators of Inflammation, vol. 2017, Article ID 9294018, 13 pages, 2017.

Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters

Academic Editor: Yona Keisari
Received25 Aug 2016
Accepted26 Dec 2016
Published18 Jan 2017


One of the hallmarks of cancer-related inflammation is the recruitment of monocyte-macrophage lineage cells to the tumor microenvironment. These tumor infiltrating myeloid cells are educated by the tumor milieu, rich in cancer cells and stroma components, to exert functions such as promotion of tumor growth, immunosuppression, angiogenesis, and cancer cell dissemination. Our review highlights the ontogenetic diversity of tumor-associated macrophages (TAMs) and describes their main phenotypic markers. We cover fundamental molecular players in the tumor microenvironment including extra- (CCL2, CSF-1, CXCL12, IL-4, IL-13, semaphorins, WNT5A, and WNT7B) and intracellular signals. We discuss how these factors converge on intracellular determinants (STAT3, STAT6, STAT1, NF-κB, RORC1, and HIF-1α) of cell functions and drive the recruitment and polarization of TAMs. Since microRNAs (miRNAs) modulate macrophage polarization key miRNAs (miR-146a, miR-155, miR-125a, miR-511, and miR-223) are also discussed in the context of the inflammatory myeloid tumor compartment. Accumulating evidence suggests that high TAM infiltration correlates with disease progression and overall poor survival of cancer patients. Identification of molecular targets to develop new therapeutic interventions targeting these harmful tumor infiltrating myeloid cells is emerging nowadays.

1. Origin of Tumor-Associated Macrophages

In 1863 Virchow described the presence of inflammatory leukocytes in tumor tissues and proposed a concept that the “lymphoreticular infiltrate” in the tumor reflects the origin of chronic inflammation at the tumor site [1]. Tumor-associated macrophages (TAMs) represent the major component of the immune infiltrate of the stroma of solid tumors, as TAMs could represent up to 50% of the tumor mass playing a key role in tumor development (Figure 1) [2]. Macrophages are heterogeneous cells with high plasticity representing a wide spectrum of activation states, ranging from the classically activated (M1 macrophages) to the alternatively activated (M2 macrophages) [3]. In cancer, macrophages are a double edged sword as they can exert both anti- and protumoral functions [4]. However until now, bad prognosis associated with high TAM content has been reported in 80% of the tumor cases [5] due to the inhibition of tumor specific immune response and promotion of neoangiogenesis and tumor cell dissemination [4, 68]. Identification of molecular targets to develop new therapeutic interventions targeting these harmful tumor infiltrating myeloid cells is emerging nowadays [9]. It has to be remarked that besides TAMs myeloid-derived suppressor cells (MDSCs) represent the major myeloid cells associated with cancer-related inflammation and cancer development. MDSCs based on their cell surface markers have been classified as monocytic (CD11b+Ly6C+ in mice and HLA-DRlow/− CD14+CD33+ in human) and granulocytic (CD11b+Ly6G+ in mice and HLA-DRlow/− CD15+CD33+ in human) subsets [7, 10]. Although MDSCs share functional and phenotypic similarities with TAMs the detailed dissection of MDSCs is beyond the scope of this review. MDSCs have recently been reviewed elsewhere [1113].

Interaction with pattern recognition receptors (which are Toll-like receptors, C-type lectins, retinoic acid inducible gene-like receptors, and nucleotide-binding oligomerization domain-like receptors) leads to the classical proinflammatory and phagocytic M1 activation of macrophages. These receptors recognize pathogen-associated molecular patterns (like LPS), resulting in the activation of innate immunity and the production of proinflammatory cytokines (IL-12, TNF-α, etc.). In addition to infections, endogenous molecules released by dying cancer cells, defined as DAMP (damage-associated molecular patterns) (e.g., high-mobility group protein B1, HMGB1, and heat shock proteins, HSPs), can activate the pattern recognition receptors and contribute to set the polarization of macrophages [14]. Moreover, classically activated macrophages are also induced by IFN-γ, alone or in concert with microbial stimuli (e.g., LPS), or cytokines (e.g., TNF-α and GM-CSF) [3].

Local signals in the tumor microenvironment (IL-4, IL-6, IL-10, PGE2, CSF-1, and transforming growth factor-β, TGF-β) polarize macrophages into alternative, protumoral M2-like cells [7]. In general M2 macrophages execute Th2 responses such as parasite clearance, dampening of inflammation, angiogenesis, and immunosuppression [7]. These protumoral functions endow M2-like TAMs to be the “Trojan horse” in the struggle against cancer (Figure 1).

Recent results have clarified the ontogenetic diversity of macrophages. Hoeffel et al. published that most of the adult tissue resident macrophages arise during fetal liver hematopoiesis from c-Myb+ fetal monocytes generated from the late c-Myb+ erythromyeloid precursors in the yolk sac [15]. Only microglia originates directly from the yolk sac precursors without monocyte intermediates [15]. Tissue resident macrophages may give rise to TAMs as it is described for microglia in glioma and for Kupffer cells in hepatocellular carcinoma [16]. It is also published that tissue resident macrophages can undergo rapid in situ proliferation under M2 polarizing Th2 cytokine milieu, specially driven by IL-4 [17]. On the other hand TAM progenitors are mainly blood circulating CCR2+ monocytes from bone marrow hematopoiesis as it is described in the case of liver, skin, brain, breast, and colon cancer [16]. Cortez-Retamozo et al. showed that TAMs may arise from the spleen, a reservoir of macrophage precursors in K-Ras driven mouse model of non-small cell lung cancer [18], and the same group published that tumor-derived angiotensin II may drive amplification of splenic macrophage progenitors [19]. Under cancer-driven emergency myelopoiesis monocytic MDSCs expand from the bone marrow and from the spleen. These monocytic MDSCs migrate to tumor microenvironment mainly by CCL2 and CSF-1 signaling and may differentiate locally into TAMs [20]. However, it is difficult to ascertain the exact origin of TAMs due to the lack of specific markers distinguishing primitive precursors, tissue resident and tissue-recruited macrophages [7, 16]. Recent review gives an overall dissection about the origin of TAMs from (embryonic or monocytic-derived) tissue resident macrophages and tumor induced, tumor infiltrating (monocytic) macrophages [4].

Molecular profiling studies revealed the expression pattern of TAMs as M2-like macrophages (Figure 2). TAMs produce proangiogenic growth factors: VEGF-A, VEGF-C, EGF, and TGF-β, metastatic enzymes: matrix metalloproteinases (MMP2, MMP9), cysteine cathepsin proteases [7, 8], immunosuppressive factors: Arginase I (ArgI), which withdraws the substrate L-arginin from inducible nitric oxide synthase (iNOS), high IL-10 and TGF-β levels, and chemokines, such as CCL2, CCL17, CCL18, CCL22, and CCL24 [8]. Moreover, alternatively activated macrophages show high YM1, FIZZ1 expression, Dectin-1high, MGLhigh, and scavenger receptorhigh profile [3, 8]. M2 macrophages express the hemoglobin scavenger receptor CD163, mannose receptor MRC1/CD206, macrophage scavenger receptor I (CD204), and macrophage galactose C-type lectin 1 (MGL1/CD301) [14, 21] as well as low levels of MHC II [22]. Nevertheless it has to be remarked that TAMs from murine fibrosarcoma model upon LPS treatment showed also typical M1 IFN-inducible cytokine expression: CCL5 (also known as RANTES), CXCL9, CXCL10, and CXCL16 due to active IRF3-dependent pathway [23]. Importantly, different tumor types or different tumor stages and tumor tissue regions are characterized by the presence of heterogeneous macrophage populations [5]. It has to be mentioned that in experimental systems it is advised and essential to define the polarization signal since different transcriptome profiles are associated with different stimuli in the M1-M2 transitions [24].

An indirect proof for the decisive role of M2 type macrophage polarization in tumor pathogenesis is provided by the antitumor effect of bacterial infections observed in diverse models. Infections seem to underlie many of the documented cases of melanoma regression [25]. The phenomenon might be analogous to the well-known antitumor effect of Coley’s toxins and other related immunomodulating strategies [26]. Interestingly, vaccination with type 1 immunity-driving pathogens was shown to provide life-long protection against melanoma by numerous large-scale clinical studies [27, 28]. The most plausible explanation is pathogen-induced alteration of macrophage polarization, as we demonstrated in our mouse model based on a case study of spontaneous melanoma regression [29].

2. Extracellular Signals Driving the Recruitment and Functions of Tumor-Associated Macrophages

Macrophages are educated by the cytokine-chemokine milieu in the tumor microenvironment where TAMs have been shown generally but not exclusively to acquire the hallmarks of alternatively activated M2 macrophages (Figure 2), associated with inhibition of inflammation and immune responses, angiogenesis, and tissue remodeling [3]. We review here the main extracellular signals which recruit and polarize M2 or M2-like tumor-associated macrophages (Figure 1).

Certain cytokines, IL-4 and IL-13, are strong inducers of an alternative (M2) form of macrophage activation [3, 7]. In addition, IL-33, a nuclear alarmin, a cytokine of the IL-1 family, is associated with Th2 and M2 polarization [30]. Another newly discovered cytokine IL-34 expressed by osteosarcoma cells sharing CSF-1R with CSF-1 recruited M2 macrophages, and its overexpression increased tumor growth, vascularization, and metastasis [31]. Macrophages can also be polarized into an “M2-like” state, which shares some but not all the signature features of M2 cells. In this regard, antibody immune complexes together with LPS or IL-1, glucocorticoids, TGF-β, and IL-10 result in M2-like functional phenotypes that share properties with IL-4- or IL-13-activated macrophages [32]. Among extracellular factors, autocrine IL-10 production also regulates TAM functions inhibiting M1 polarization through suppression of IL-12 [33]. The tumor promoting phenotype of CD14+ blood monocytes and TAMs was IL-1β-IL1R axis dependent in human renal cell carcinoma patients [34]. Myeloid compartment specific deficiency in TGF-β receptor II showed lower susceptibility to DSS induced colitis-associated cancer along with lower percentage of F4/80+ TAM infiltration and downregulation of STAT3 phosphorylation in the colonic adenoma tissue [35]. Further reinforce the role of TGF-β in cancer-related inflammation that TGF-β not only recruits and polarizes M2 macrophages but also regulates their MMPs expression, which in a mutual response release more TGF-β from extracellular matrix store [36]. TGF-β plays an important role in the regulation of inflammation since TGF-β might contribute to Th17 differentiation and the release of IL-17 [37]. Interleukin-17 has been shown to play a role in the recruitment of IL17RA and IL17RC expressing TAMs in lung cancer [38].

A series of chemoattractants, chemokines, orchestrate the recruitment of monocytes/macrophages; the chemokine CCL2 (also known as MCP-1) was first discovered as a tumor-derived chemotactic factor which recruits these cells to tumor tissues [39]. Several studies reported the pivotal role of tumor cell- or tumor-associated stroma-derived CCL2, as master regulator of monocyte/macrophage recruitment to the tumor site [7]. Along with IL-6, CCL2 also promotes survival and differentiation of myeloid monocytes [40]. In oral carcinoma the tumor cell-produced β-defensin-3 (hBD3, which was discovered as an antimicrobial peptide) has been associated with CCR2 dependent TAM trafficking [41]. The Ca2+ binding S100 proteins, released from, for example, necrotic cells of the tumor mass, serve as DAMPs, alarmin molecules to the immune system; one member, the S100B molecule, promoted glioma growth by TAM chemoattraction through CCL2 upregulation and induction of STAT3 [42]. Another Ca2+ binding S100 protein, S100A9, level correlated with high CD11b+ myeloid cell infiltration and increased tumor growth in murine breast cancer model [43]. Eruslanov et al. showed elevated CCL1 expression both in human tumor cells and in CD11b+CCR8+ myeloid cells of human bladder and renal cell carcinomas. The circulating monocytic CD33highCD11b+ and granulocytic CD33lowCD11b+ myeloid cell subset as well as CD11b+ tumor infiltrating TAMs showed increased expression of the CCL1 chemokine receptor CCR8. The tumor infiltrating CD11b+CCR8+ myeloid subset produced significant amount of proinflammatory IL-6 and angiogenic VEGF and induced the differentiation of CD4+FoxP3+ regulatory T-cells [44]. Semaphorins were discovered as axonal growth cone guidance molecules; semaphorin 3B induced CXCL8 (IL-8) production by tumor cells in a Neuropilin-1 dependent manner, which recruited TAMs fostering a prometastatic environment surprisingly with tumor reduction [45]. Hypoxia induced another member of the group, semaphorin 3A, which attracted TAMs via PlexinA1/PlexinA4 and Neuropilin-1 holoreceptor followed by VEGFR1 activation leading to immunosuppression and angiogenesis. Deletion of Neuropilin-1 favored TAM localization in normoxic tumor regions hampering their angiogenic and immunosuppressive functions, thereby impeding tumor growth and metastasis [46]. Stromal cell-derived factor-1 (SDF-1), also known as CXCL12, drives TAM accumulation and survival in hypoxic areas of tumors [47]. CXCL12 also enhances the scavenger receptor CD163 and VEGF expression, shaping monocyte differentiation toward proangiogenic and immunosuppressive phenotype [48]. Fractalkine, another chemokine, CX3CL1, has also been implicated in the recruitment of macrophages since the administration of anti-CX3CR1 antibody decreased macrophage infiltration and angiogenesis in breast cancer [49].

Tumor cells or tumor-associated stromal cells produce hematopoietic growth factors (CSF-1, GM-CSF, and IL-34) which increase the expansion of the monocyte-macrophage lineage [5]. Inhibition of colony-stimulating factor-1 (CSF-1, also known as M-CSF), the primary regulator of tissue macrophage production, or the blockade of CSF-1 receptor (also known as CD115 or c-fms) led to decreased macrophage infiltration and less mammary tumor growth [50]. Depletion of CD115+ F4/80+ macrophages during early hyperplastic stage with anti-CSF-1R antibody (M279) reduced primary tumor growth and lung metastasis [51]. CSF-1 influences also the maturation of tumor-associated macrophages; in CSF-1 deficient animals macrophages remained more immature with lower expression of IL-1β, TNF-α [52]. Small interfering RNA against CSF-1 caused decreased neuroblastoma tumor growth with less macrophage infiltration, lower MMP12 level, and angiogenesis [53]. It has been published that STAT1 binds to Csf1 promoter in tumor cells; by this way STAT1 could regulate breast tumor-derived CSF-1 production which drives to the recruitment, in situ proliferation, and M2 phenotype of CD11blow F4/80high TAMs [54].

Not only cytokines, chemokines, and growth factors but also other types of molecules, signal transducers, could influence or determine the M2/M2-like polarization of TAMs. The Wnt gene family consists of lipid modified signaling glycoproteins; the WNT5A expression in human breast tumors correlated with the number of CD163+ TAMs, along with induction of immunosuppressive IL-10 and TGF-β [55]. Another Wnt family member WNT7B showed colocalization with CD68+/CD163+ TAMs. Tumor growth in this MMTV-PymT-driven mouse breast cancer was dependent on the WNT7B expression by myeloid cells since in the CSF-1R promoter dependent conditional knock-out model the myeloid selective ablation of Wnt7b reduced tumor growth beyond the failure of the angiogenic switch [56]. In renal cell carcinoma patients, the triple positivity for bone morphogenetic protein-6 (BMP-6, a member of the TGF-β superfamily) and CD68 as well as IL-10 positivity in biopsies was correlated with worse cumulative survival, indicating that BMP-6 induces M2 macrophage polarization with IL-10 production via activation of Smad5 and STAT3 [57]. The expression of TREM-1 (triggering receptor expressed on myeloid cells 1, a receptor belonging to the immunoglobulin superfamily) mainly on monocytes/macrophages has been implicated in the severity of chronic inflammation and malignancies [58]. Yuan et al. proposed a mechanism in which tumor cell-derived cyclooxygenase-2 (Cox-2) dependent PGE2 induces TREM-1 expression in CD68+ TAMs via EP1/EP4 receptors [59]. The same group has also published that TREM-1 prolongs the survival of macrophages through the induction of the antiapoptotic protein Bcl-2 [60]. Both tumor and tumor stroma-derived Cox-2 are associated with poor prognosis. Chen et al. described that myeloid specific ablation of Cox-2 reduced tumor burden and TAM infiltration. Moreover Cox-2 deficiency lowered the M2 immunosuppressive profile of TAMs and enhanced CD8+ T-cell immunosurveillance [61].

3. Intracellular Determinants of the Recruitment and Functions of Tumor-Associated Macrophages

The inflammatory milieu of the tumor microenvironment affects different intracellular master regulators of TAMs such as Signal Transducer and Activator of Transcription factors (STAT3 and STAT6 for M2, STAT1 for M1 polarization), the nuclear factor-κB (NF-κB), RORC1, and HIF-1. Classical M1 and alternative M2 polarizing determinants are outlined in Figure 2.

Tumor infiltrating myeloid cells undergo a functional change in response to STAT3 activation. This event promotes angiogenesis through VEGF and bFGF induction [62]. STAT3 activation is a key determinant establishing tolerance during immune escape, both in adaptive and in innate effector cells [63]. A pioneer study by Cheng et al. reported that disruption of STAT3 signaling in macrophages or in bone marrow-derived dendritic cells restored the responsiveness of tolerant T-cells from tumor bearing mice [64]. The same group published that the ablation of STAT3 in the hematopoietic compartment combined with CpG treatment resulted in the rapid activation of the innate immunity (high IL-12, TNF-α) which forced T-cell response leading to regression of preestablished B16 melanoma tumors [65]. Recently the same group further explored the role of STAT3 in myeloid cells establishing cancer favoring microenvironment. T-cells exert immunosurveillance and constrain myeloid cell accumulation in premetastatic tissue, but this is resisted by STAT3 in myeloid cells. Ablation of STAT3 in myeloid cells led to higher T-cell activation, higher IFN-γ, granzyme B production, and consequently myeloid cell apoptosis in the premetastatic niche [6]. The inhibition of STAT3 phosphorylation by oleanolic and corosolic acids, two naturally occurring triterpenes, suppressed tumor-mediated M2 polarization and IL-10 production by macrophages [66]. Other dietary compounds, including n-3 polyunsaturated fatty acids (PUFAs), which have been described as anti-inflammatory and anticancer agents [67, 68], have been recently shown to alter M2 macrophage polarization during the inflammatory response in colon tissue by targeting the epigenetic regulation of gene expression [69]. This novel finding might open new therapeutic potential for dietary PUFAs; however more studies are needed to clarify their potential role in modulating TAMs in cancer. Lovastatin, a cholesterol biosynthesis inhibitor, enhanced tumor infiltration by effector T-cells and reduced the number of immunosuppressive and proangiogenic M2-like TAMs [70]. According to our previous results, where we showed that PUFAs can modulate cholesterol induced inflammatory gene expression [71], we speculate that lipid homeostasis in the tumor microenvironment might have direct or indirect role in macrophage polarization and in local immune functions.

STAT6 is also associated with M2 polarization and STAT6−/− mice showed less tumor growth and metastasis due to enhanced CD8+ Th1 response [72]. The same group reported that survival of tumor bearing STAT6−/− mice and reduction in metastasis are dependent on the restored capacity of TAMs to produce tumoricidal NO [73]. STAT6, in cooperation with Krüppel-like faktor-4 (KLF-4), induces a series of genes responsible for skewing macrophages toward M2, for example, mannose receptor (CD206), Ym1, Fizz1, ArgI, PPAR-γ [74], and inhibits M1 genes like TNF-α, CCL5, and iNOS [32].

Whereas STAT3 and STAT6 activation occurs in response to M2 signals (IL-10 or IL-4, resp.), STAT1 is activated by M1 polarizing signals (LPS or IFN-γ) [75]. IFN-γ triggers JAK-mediated tyrosine phosphorylation and dimerization of STAT1 which is fundamental for its DNA binding to various M1 promoter genes (e.g., iNOS, MHCII, and IL-12) [74]. STAT1 also mediates the expression of SOCS3 which inhibits STAT3 activation [76].

In the tumor microenvironment release of danger-associated molecular patterns (e.g., HMGB1, HSPs), IL-1β and TNF-α lead to NF-κB activation and translocation of the p65/p50 heterodimer to the nucleus which favors M1 polarization of macrophages although accumulation of the p50 inhibitory homodimer mediates defective responsiveness of TAMs and M2 polarization, associated with inhibition of proinflammatory mediators [77, 78]. TAMs from NF-κB p50−/− tumor bearing mice showed M1 profile (IL-12high/IL-10low), paralleled by increase in vivo production of the Th1 cytokines (IFN-γ) by splenocytes and delayed tumor growth [77]. Activation of NF-κB is controlled by IκB kinase β (IKKβ). However, IKKβ activity is also required to inhibit the M1 or “classical” macrophage activation, resulting in inhibition of STAT1-driven gene expression and downmodulation of IL-12, MHCII, and iNOS expression [79]. The deletion of IKKβ restored TAM responsiveness which was manifested in tumor growth inhibition, low IL-10, low ArgI, and high IL-12 production [80]. Negative regulators of TLR signaling or NF-κB activation (SIGIRR/TIR8, SHIP1, and SOCS1) have been shown to contribute to the tolerant phenotype of macrophages [81]. TGF-β dependent induction of IRAK-M, an inactive serine/threonine kinase, was associated with the M2 phenotype of TAM in a mouse model of lung cancer [82]. Interestingly, IRAK-M expression was paralleled by altered epigenetic regulation, where ERK1/2 activation in a MyD88-independent way caused histone modifications at the IL-10 promoter gene, activating its transcription [83].

The generation of TAMs relies on the persistent stimulation by signals of the chronic inflammatory tumor microenvironment. We recently identified retinoic-acid-related orphan receptor (RORC1/RORγ) as a key driver of the differentiation of TAMs and MDSCs during “emergency” granulomonocytopoiesis in cancer. RORC1 suppresses negative regulators (SOCS3 and Bcl3) and promotes not only positive regulators of granulomonocytopoiesis (CEBPβ, PU.1) but also the maturation of macrophages (IRF8). RORC1 facilitates the accumulation of immunosuppressive immature MDSCs, prolongs their survival, and polarizes TAMs to M2-like tumor promoting phenotype [10].

Hypoxia (low oxygen tension) is a hallmark feature of almost all solid tumors, often characterized by high infiltration of macrophages, contributing to angiogenesis [84], cytotoxic T-lymphocyte suppression, and tumor progression [85, 86]. Hypoxia stabilizes HIF-1α, a prototypical member of the family of hypoxia-inducible transcription factors, by preventing its ubiquitination and subsequent proteasomal degradation. This event results in dimerization of HIF-1α with the HIF-1β subunit and its nuclear translocation to activate the transcription of genes involved in the cellular adaptation to low oxygen supply. Hypoxic tumor microenvironment also has a fundamental effect on myeloid cell infiltrate which is linked to HIF-1 and HIF-2 factors (HIFs) [84]. Group of Semenza delineated one mechanism in the establishment of hypoxia (HIFs) induced deleterious tumor stroma organization. Hypoxia induces CCL5 expression in mesenchymal stem cells which binds also to hypoxia induced CCR5 in breast cancer cells leading to higher tumoral CSF-1 expression which drives the recruitment of TAMs and MDSCs. The recruitment of these myeloid cells promotes breast tumor growth and metastasis [87]. While hypoxia activates NF-κB through the activation of IKKβ [88], NF-κB is also a critical transcriptional activator of HIF-1α in macrophages [89]. It was reported that HIF-2α deficient TAMs expressed lower levels of the chemokine receptor CXCR4 and failed to accelerate tumor growth [90]. Accumulating evidence suggests that tumor infiltrating myeloid cells support tumor development, wherein hypoxia can promote myeloid cell mobilization and homing to tumors through the CXCL12-CXCR4 axis. In the local hypoxic areas of the tumor microenvironment HIF-1α triggers CXCL12 (SDF-1) expression which in turn increases migration, adhesion, and homing of CXCR4+ progenitors [91]. As a positive regulatory loop hypoxia further increases the chemotactic responsiveness of monocytes/macrophages through the HIF-1α-mediated upregulation of CXCR4 [92]. Moreover, hypoxia can mediate MDSC expansion and recruitment from the spleen to the tumor microenvironment and convert them from specific to nonspecific suppressors, promoting their differentiation to TAMs [85]. It has been reported that hypoxia also augments macrophage-mediated T-cell suppression, as targeted deletion of HIF1-α in macrophages inhibited ArgI production and T-cell suppression, resulting in tumor growth inhibition [86]. The immune regulator, programmed death-1 ligand-1 (PD-L1), has been identified as a HIF-1α dependent specific factor and potential therapeutic target upregulated by hypoxia in splenic MDSCs and TAMs in murine lung, breast, and colon cancer and melanoma [93]. Laoui et al. showed that tumor infiltrating Ly6Chi monocytes give rise to both MHCIIhi and MHCIIlow CD11b+F4/80+ macrophages in Lewis lung carcinoma (LLC) model. The latter localized mainly in hypoxic regions with higher expression of typical M2 markers. The prolyl-hydroxylase domain 2 haplodeficiency with the phenotype of vessel normalization did not alter M1/M2 TAM distribution rather diminished the expression of hypoxia regulated M2 associated genes and proangiogenic activity of MHCIIlow CD11b+F4/80+ macrophages [94]. HIF-1 has been identified to link the inflammatory and oncogenic pathways, as it was shown that IL-1β upregulated HIF-1α protein through a classical inflammatory signaling pathway involving NF-kB and COX-2 [95].

New molecular players have been identified in TAM polarization as potential candidates or targets of therapeutic interventions. It has been described that the TSC2-mTOR pathway is a key determinant in the differentiation of monocytes to M2 angiogenic macrophages, and the mTOR inhibitor rapamycin caused M1 polarization. On the contrary when mTOR was active, knocking-down the intrinsic mTOR inhibitor TSC2, TAMs produced more IL-10 and both tumor growth and angiogenesis increased [96]. Forced signaling of Notch increased M1 macrophages with IL-12 production, whereas compromised Notch signaling caused M2 polarization of macrophages favoring B16 melanoma and LLC lung carcinoma tumor growth [97]. Among tumor infiltrating leukocytes TAMs produced the mitogen Gas6 accelerating primary tumor growth and metastasis [98]. During alternative activation of macrophages IL-4 induced c-myc upregulated STAT6 and PPAR-γ, thus contributing to the protumoral phenotype of TAM [99]. Specific ablation of Ron receptor tyrosine kinase in the myeloid compartment inhibited prostate cancer growth which was restored by the depletion of CD8+ but not CD4+ T-cells [100]. TNF receptor-associated factor 2 (TRAF-2) suppresses the proinflammatory cytokine production in macrophages. Recently it has been published that TRAF-2 controls the fate of IRF5 and c-Rel by proteasomal degradation via TRAF3 and cIAP. Myeloid cell specific deletion of TRAF-2 resulted in less tumor growth and lower TAM infiltration along with higher intratumoral IFN-γ produced by higher percentage of CD4+ and CD8+ T-cell infiltration [101].

4. Posttranscriptional Regulation and Role of MicroRNAs in the Polarization of Tumor-Associated Macrophages

Nowadays, the regulatory role of microRNAs (miRNAs) that control both physiological and pathological processes is under intensive investigation. The last decade has seen an explosion of knowledge about miRNAs in cancer, hematopoiesis, and inflammation. As mutations of oncogenes or tumor suppressors, deregulation of miRNAs can drive oncogenesis and tumor progression. The nonneoplastic cells in the tumor stroma, as TAMs, also show an altered miRNAs expression. Although miRNAs regulate posttranscriptional gene expression intracellularly these regulators are not considered only intracellular determinants of the polarization of macrophages in this review since intercellular communication by miRNA transporting exosomes has been described not only between malignant cells and TAMs but also among the variety of cellular components of the inflammatory microenvironment [102104]. A complete overview of miRNAs in terms of cancer-related inflammation is beyond the scope of this review; we summarize the recent results on the effects of key miRNAs on monocyte/macrophage lineage development and on the polarization of TAMs. The detailed summary of miRNAs in relation to macrophage polarization and immune response is recently reviewed elsewhere [105, 106].

The miR-146 family includes two members: miR-146a and miR-146b. Although their sequences differ only in two nucleotides, they are encoded on different chromosomes [107]. In 2006 Taganov and his colleagues showed the NF-κB dependent upregulation of the endotoxin responsive (TLR2-, TLR4-, and TLR5-dependent) miR-146a in the THP-1 human monocytic cell line. They identified interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) adaptor molecules as the main targets of miR-146a in the TLR pathway [108]. MiR-146a represents a negative feedback loop dampening the signals upstream NF-κB, with relevance in endotoxin induced tolerance [109]. MiR-146a promotes the binding of the transcriptional repressor Relb to the TNF-α promoter, leading to the inhibition of TNF-α expression. In addition, miR-146a also promotes RBM4-Ago2 interaction, with the assembly of the miRNA-induced silencing complex which disrupts translation of TNF-α in THP-1 cells [110]. It has been published in a Listeria monocytogenes infection model that miR-146a controls the expansion and recruitment of inflammatory monocyte precursors by targeting Relb and CCR2 in the Ly6Chigh subset [111]. Induced expression of miR-146a in glioma cells has been reported upon DHA treatment and irradiation with 10 Gy [112]. Curtale et al. showed that the anti-inflammatory activity of IL-10 at least partly relies on the induction of miR-146b on a STAT3 dependent manner; miR-146b modulates TLR4 signaling pathway by dampening MyD88, IRAK1, and TRAF6 [113].

In two different comparative studies, performed with bone marrow-derived macrophages (BMDMs), M1 polarization by LPS/IFN-γ induced miR-155, while M2 polarization by IL-4 induced miR-146a [114, 115]. miR-155 is also upregulated in macrophages by NF-κB activation, via stimulation of TLR2, TLR4, TLR5, and TLR9 [116]. Interestingly, miR-155 targets negative regulators of inflammation: suppressor of cytokine signaling 1 (SOCS1) [117], B-cell lymphoma-6 protein (BCL6) [118], and Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1) [119]. Moreover, miR-155 silences IL-13 receptor (IL13RA) which promotes M2 polarization of macrophages [120], stabilizes the TNF-α transcript, by increasing its half-life [121], and targets CEBP/β, which is an M2 associated transcription factor with increased activity in TAMs [122, 123]. MiR-155−/− mice showed increased tumor growth [124] and miR-155 in vivo knockdown in the myeloid compartment impaired the ability of these cells to mount a proinflammatory response, which also increased tumor growth [125]. In accordance with the aforementioned observations, miR-155 overexpressing TAMs were repolarized from M2 to M1 ex vivo [115]. In chronic inflammation elevated levels of miR-155 downregulate mismatch repair proteins [126] and block the cell-cycle regulatory WEE1 kinase [127]; this promutagenic activity of miR-155 further forces the link between inflammation and cancer.

The experimental results about the role of miRNAs in the polarization of myeloid cells such as macrophages are often controversial due to the different cell types, stimuli, and tumor models used in the studies of different laboratories [106]. In human metastatic breast cancer patients the CSF1-R+ myeloid cells showed CSF1-ETS2 induced higher expression of miR-21 and miR-29a which correlated with higher metastatic tumor burden [128]. However, Wang et al. reported that miR-21 as an endogenous brake prevents PGE2 mediated M2 polarization via targeting STAT3 in murine peritoneal macrophages [129]. The passenger strand of miR-511 is the bioactive strand (miR-511-3p) which is encoded within the fifth intron of MRC1 (macrophage mannose receptor, CD206) gene. Hence, during alternative (M2-like) activation of macrophages MRC1 expression is accompanied by miR-511-3p synthesis. Surprisingly, the overexpression of miR-511-3p in hematopoietic cells inhibited LLC tumor growth, disrupted vessel morphology, and as a negative regulator tuned down protumoral genes such as matrix remodeling enzymes, scavenger receptors, and TGF-β. Squadrito et al. showed that miR-511-3p targets Rho-associated coiled-coil containing protein kinase 2 (Rock2), a serine-threonine kinase that phosphorylates IRF4, a transcription factor that promotes M2 activation of macrophages [130]. In this way miR-511 serves to establish a threshold, as an endogenous molecular “brake” to suppress the M2 polarization of TAMs. Chaudhuri et al. reported that overexpression of miR-125b mediated M1 polarization and increased the response of macrophages to IFN-γ which resulted in higher MHCII, CD40, CD80, and CD86 expression; moreover miR-125b overexpressing RAW264.7 macrophages were more effective killers of EL4 thymoma tumor cell line [131]. Banerjee et al. differentiated murine bone marrow cells by GM-CSF (GM-BMM) and CSF-1 (M-BMM) to establish macrophage cultures. TLR2 and TLR4 ligands upregulated miR-125a-5p on MyD88 dependent manner. Overexpression of miR-125a-5p in GM-CSF differentiated macrophages reduced M1 cytokine production (IL-12, TNF-α, and iNOS) and increased Arg1, characteristic of M2 phenotype, upon IL-4 treatment. Surprisingly miR-125a-5p overexpression diminished the bactericidal activity in contrast increased phagocytic activity of GM-BMM cells [132]. Forced activation of Notch repressed tumor growth and subverted TAM phenotype to IL-12high and iNOShigh; furthermore active Notch signaling downstream upregulated miR-125a in bone marrow-derived macrophages (BMDM) mainly by LPS+IFN-γ stimuli. MiR-125a mimetics promoted IL-12, iNOS, and TNF-α expression in BMDMs and restored T-cell proliferation. Finally, Zhao et al. concluded that miR-125a targets the suppressor of HIF-1α, FIH1, and IRF4 to promote M1 and suppresses M2 polarization of macrophages. [133]. The inconsistency about the M1 or M2 promoting role of miRNA125a may arise from the different source of cells and stimuli used by different laboratories so further studies should clarify this discrepancy. Another miRNA, miRNA let-7b, has been shown to be upregulated in prostatic TAMs (established by the incubation of human blood monocytes with PCa prostate cancer cell conditioned medium) and modulates IL-12, IL-23, IL-10, and TNF-α and promotes mobility of PCa cells and proangiogenesis of PCa-conditioned TAMs [134]. Inhibition or macrophage specific deletion of miR-33, a miRNA playing role in cellular metabolism, increased oxidative phosphorylation and induced M2 polarization associated gene profile (ArgIhigh, Mrc1high); additionally miR-33 deficient macrophages promoted the differentiation of T regulatory cells. MiR-33 regulates macrophage inflammation via targeting of AMP-activated protein kinase thereby promoting glycolysis and M1 polarization [135].

MiR-223 has been described as a novel regulator of macrophage polarization targeting Pknox1 transcription factor; miR-223 limits proinflammatory activation of macrophages and enhances the alternative anti-inflammatory responses [136].

5. Conclusions

In conclusion, accumulating evidence suggests that further identification of novel molecules and mechanisms involved in macrophage recruitment and/or polarization offers the basis for novel therapeutic approaches against harmful myeloid cells educated by the developing tumors. Reeducating TAMs, tuning the balance from M2 to M1 in the tumor microenvironment might be a holy grail of macrophage-targeted therapies.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.


The present work was partially supported by Grants GINOP-2.3.2-15-2016-00001 for Csaba Vizler, Laszlo G. Puskas, and Klara Kitajka and GINOP-2.3.2-15-2016-00030 for Laszlo G. Puskas and Klara Kitajka from the National Research, Development and Innovation Office (NKFI), Hungary.


  1. A. Mantovani, B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco, “The origin and function of tumor-associated macrophages,” Immunology Today, vol. 13, no. 7, pp. 265–270, 1992. View at: Publisher Site | Google Scholar
  2. J. Kim and J.-S. Bae, “Tumor-associated macrophages and neutrophils in tumor microenvironment,” Mediators of Inflammation, vol. 2016, Article ID 6058147, 11 pages, 2016. View at: Publisher Site | Google Scholar
  3. A. Sica, M. Erreni, P. Allavena, and C. Porta, “Macrophage polarization in pathology,” Cellular and Molecular Life Sciences, vol. 72, no. 21, pp. 4111–4126, 2015. View at: Publisher Site | Google Scholar
  4. R. A. Franklin and M. O. Li, “Ontogeny of tumor-associated macrophages and its implication in cancer regulation,” Trends in Cancer, vol. 2, no. 1, pp. 20–34, 2016. View at: Publisher Site | Google Scholar
  5. D. Laoui, E. Van Overmeire, P. De Baetselier, J. A. Van Ginderachter, and G. Raes, “Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression,” Frontiers in Immunology, vol. 5, article 489, 2014. View at: Publisher Site | Google Scholar
  6. W. Zhang, C. Zhang, W. Li et al., “CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation,” European Journal of Immunology, vol. 45, no. 1, pp. 71–81, 2015. View at: Publisher Site | Google Scholar
  7. N. Caronni, B. Savino, and R. Bonecchi, “Myeloid cells in cancer-related inflammation,” Immunobiology, vol. 220, no. 2, pp. 249–253, 2015. View at: Publisher Site | Google Scholar
  8. S. K. Biswas, P. Allavena, and A. Mantovani, “Tumor-associated macrophages: functional diversity, clinical significance, and open questions,” Seminars in Immunopathology, vol. 35, no. 5, pp. 585–600, 2013. View at: Publisher Site | Google Scholar
  9. G. J. Szebeni, C. Vizler, L. I. Nagy, K. Kitajka, and L. G. Puskas, “Pro-tumoral inflammatory myeloid cells as emerging therapeutic targets,” International Journal of Molecular Sciences, vol. 17, no. 11, p. 1958, 2016. View at: Publisher Site | Google Scholar
  10. L. Strauss, S. Sangaletti, F. M. Consonni et al., “RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis,” Cancer Cell, vol. 28, no. 2, pp. 253–269, 2015. View at: Publisher Site | Google Scholar
  11. A. R. Pyzer, L. Cole, J. Rosenblatt, and D. E. Avigan, “Myeloid-derived suppressor cells as effectors of immune suppression in cancer,” International Journal of Cancer, vol. 139, no. 9, pp. 1915–1926, 2016. View at: Publisher Site | Google Scholar
  12. V. Kumar, S. Patel, E. Tcyganov, and D. I. Gabrilovich, “The nature of myeloid-derived suppressor cells in the tumor microenvironment,” Trends in Immunology, vol. 37, no. 3, pp. 208–220, 2016. View at: Publisher Site | Google Scholar
  13. V. Bronte, S. Brandau, S.-H. Chen et al., “Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards,” Nature Communications, vol. 7, Article ID 12150, 2016. View at: Publisher Site | Google Scholar
  14. C. Porta, E. Riboldi, A. Ippolito, and A. Sica, “Molecular and epigenetic basis of macrophage polarized activation,” Seminars in Immunology, vol. 27, no. 4, pp. 237–248, 2015. View at: Publisher Site | Google Scholar
  15. G. Hoeffel, J. Chen, Y. Lavin et al., “C-Myb+ erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages,” Immunity, vol. 42, no. 4, pp. 665–678, 2015. View at: Publisher Site | Google Scholar
  16. E. Van Overmeire, D. Laoui, J. Keirsse, J. A. Van Ginderachter, and A. Sarukhan, “Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues,” Frontiers in Immunology, vol. 5, article 127, 2014. View at: Publisher Site | Google Scholar
  17. S. J. Jenkins, D. Ruckerl, P. C. Cook et al., “Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation,” Science, vol. 332, no. 6035, pp. 1284–1288, 2011. View at: Publisher Site | Google Scholar
  18. V. Cortez-Retamozo, M. Etzrodt, A. Newton et al., “Origins of tumor-associated macrophages and neutrophils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2491–2496, 2012. View at: Publisher Site | Google Scholar
  19. V. Cortez-Retamozo, M. Etzrodt, A. Newton et al., “Angiotensin II drives the production of tumor-promoting macrophages,” Immunity, vol. 38, no. 2, pp. 296–308, 2013. View at: Publisher Site | Google Scholar
  20. S. Ugel, F. De Sanctis, S. Mandruzzato, and V. Bronte, “Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages,” The Journal of Clinical Investigation, vol. 125, no. 9, pp. 3365–3376, 2015. View at: Publisher Site | Google Scholar
  21. Y. De Vlaeminck, A. González-Rascón, C. Goyvaerts, and K. Breckpot, “Cancer-associated myeloid regulatory cells,” Frontiers in Immunology, vol. 7, article 113, 2016. View at: Publisher Site | Google Scholar
  22. B. Wang, Q. Li, L. Qin, S. Zhao, J. Wang, and X. Chen, “Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice,” BMC Immunology, vol. 12, article 43, 2011. View at: Publisher Site | Google Scholar
  23. S. K. Biswas, L. Gangi, S. Paul et al., “A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation),” Blood, vol. 107, no. 5, pp. 2112–2122, 2006. View at: Publisher Site | Google Scholar
  24. P. Murray, J. Allen, S. Biswas et al., “Macrophage activation and polarization: nomenclature and experimental guidelines,” Immunity, vol. 41, no. 1, pp. 14–20, 2014. View at: Publisher Site | Google Scholar
  25. L. V. Kalialis, K. T. Drzewiecki, and H. Klyver, “Spontaneous regression of metastases from melanoma: review of the literature,” Melanoma Research, vol. 19, no. 5, pp. 275–282, 2009. View at: Publisher Site | Google Scholar
  26. S. Patyar, R. Joshi, D. S. P. Byrav, A. Prakash, B. Medhi, and B. K. Das, “Bacteria in cancer therapy: a novel experimental strategy,” Journal of Biomedical Science, vol. 17, no. 1, article no. 21, 2010. View at: Publisher Site | Google Scholar
  27. B. Krone, K. F. Kölmel, J. M. Grange et al., “Impact of vaccinations and infectious diseases on the risk of melanoma—evaluation of an EORTC case-control study,” European Journal of Cancer, vol. 39, no. 16, pp. 2372–2378, 2003. View at: Publisher Site | Google Scholar
  28. A. Pfahlberg, K. F. Kölmel, J. M. Grange et al., “Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study,” Journal of Investigative Dermatology, vol. 119, no. 3, pp. 570–575, 2002. View at: Publisher Site | Google Scholar
  29. K. Buzás, A. Marton, C. Vizler et al., “Bacterial sepsis increases survival in metastatic melanoma: chlamydophila pneumoniae induces macrophage polarization and tumor regression,” Journal of Investigative Dermatology, vol. 136, no. 4, pp. 862–865, 2016. View at: Publisher Site | Google Scholar
  30. S. P. Gadani, J. T. Walsh, I. Smirnov, J. Zheng, and J. Kipnis, “The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury,” Neuron, vol. 85, no. 4, pp. 703–709, 2015. View at: Publisher Site | Google Scholar
  31. A. I. Ségaliny, A. Mohamadi, B. Dizier et al., “Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment,” International Journal of Cancer, vol. 137, no. 1, pp. 73–85, 2015. View at: Publisher Site | Google Scholar
  32. M. Locati, A. Mantovani, and A. Sica, “Macrophage activation and polarization as an adaptive component of innate immunity,” Advances in Immunology, vol. 120, pp. 163–184, 2013. View at: Publisher Site | Google Scholar
  33. A. Sica, A. Saccani, B. Bottazzi et al., “Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages,” Journal of Immunology, vol. 164, no. 2, pp. 762–767, 2000. View at: Publisher Site | Google Scholar
  34. M. Chittezhath, M. K. Dhillon, J. Y. Lim et al., “Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression,” Immunity, vol. 41, no. 5, pp. 815–829, 2014. View at: Publisher Site | Google Scholar
  35. J. Li, Y. Liu, B. Wang et al., “Myeloid TGF-β signaling contributes to colitis-associated tumorigenesis in mice,” Carcinogenesis, vol. 34, no. 9, pp. 2099–2108, 2013. View at: Publisher Site | Google Scholar
  36. J. Krstic and J. F. Santibanez, “Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells,” The Scientific World Journal, vol. 2014, Article ID 521754, 14 pages, 2014. View at: Publisher Site | Google Scholar
  37. B. Yang, H. Kang, A. Fung, H. Zhao, T. Wang, and D. Ma, “The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis,” Mediators of Inflammation, vol. 2014, Article ID 623759, 12 pages, 2014. View at: Publisher Site | Google Scholar
  38. L. Liu, D. Ge, L. Ma et al., “Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer,” Journal of Thoracic Oncology, vol. 7, no. 7, pp. 1091–1100, 2012. View at: Publisher Site | Google Scholar
  39. A. Mantovani, W. J. Ming, C. Balotta, B. Abdeljalil, and B. Bottazzi, “Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 865, no. 1, pp. 59–67, 1986. View at: Publisher Site | Google Scholar
  40. H. Roca, Z. S. Varcos, S. Sud, M. J. Craig, and K. J. Pienta, “CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization,” Journal of Biological Chemistry, vol. 284, no. 49, pp. 34342–34354, 2009. View at: Publisher Site | Google Scholar
  41. G. Jin, H. I. Kawsar, S. A. Hirsch et al., “An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis,” PLoS ONE, vol. 5, no. 6, article 10993, 2010. View at: Publisher Site | Google Scholar
  42. H. Wang, L. Zhang, I. Y. Zhang et al., “S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages,” Clinical Cancer Research, vol. 19, no. 14, pp. 3764–3775, 2013. View at: Publisher Site | Google Scholar
  43. A. Becker, N. G. Hokamp, S. Zenker et al., “Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction,” Journal of Nuclear Medicine, vol. 56, no. 3, pp. 450–456, 2015. View at: Publisher Site | Google Scholar
  44. E. Eruslanov, T. Stoffs, W.-J. Kim et al., “Expansion of CCR8+ inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas,” Clinical Cancer Research, vol. 19, no. 7, pp. 1670–1680, 2013. View at: Publisher Site | Google Scholar
  45. C. Rolny, L. Capparuccia, A. Casazza et al., “The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment,” The Journal of Experimental Medicine, vol. 205, no. 5, pp. 1155–1171, 2008. View at: Publisher Site | Google Scholar
  46. A. Casazza, D. Laoui, M. Wenes et al., “Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity,” Cancer Cell, vol. 24, no. 6, pp. 695–709, 2013. View at: Publisher Site | Google Scholar
  47. S.-C. Wang, J.-H. Hong, C. Hsueh, and C.-S. Chiang, “Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model,” Laboratory Investigation, vol. 92, no. 1, pp. 151–162, 2012. View at: Publisher Site | Google Scholar
  48. L. Sánchez-Martín, A. Estecha, R. Samaniego, S. Sánchez-Ramón, M. Á. Vega, and P. Sánchez-Mateos, “The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression,” Blood, vol. 117, no. 1, pp. 88–97, 2011. View at: Publisher Site | Google Scholar
  49. J. R. Reed, M. D. Stone, T. C. Beadnell, Y. Ryu, T. J. Griffin, and K. L. Schwertfeger, “Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner,” PLoS ONE, vol. 7, no. 9, Article ID e45877, 2012. View at: Publisher Site | Google Scholar
  50. S. Aharinejad, P. Paulus, M. Sioud et al., “Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice,” Cancer Research, vol. 64, no. 15, pp. 5378–5384, 2004. View at: Publisher Site | Google Scholar
  51. A.-J. Casbon, M. Lohelay, and Z. Werb, “Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors,” OncoImmunology, vol. 4, no. 6, Article ID e1008871, 2015. View at: Publisher Site | Google Scholar
  52. S. T. Dougherty, C. J. Eaves, W. H. McBride, and G. J. Dougherty, “Role of macrophage-colony-stimulating factor in regulating the accumulation and phenotype of tumor-associated macrophages,” Cancer Immunology Immunotherapy, vol. 44, no. 3, pp. 165–172, 1997. View at: Publisher Site | Google Scholar
  53. D. Abraham, K. Zins, M. Sioud et al., “Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma,” International Journal of Cancer, vol. 126, no. 6, pp. 1339–1352, 2010. View at: Publisher Site | Google Scholar
  54. P. Tymoszuk, H. Evens, V. Marzola et al., “In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors,” European Journal of Immunology, vol. 44, no. 8, pp. 2247–2262, 2014. View at: Publisher Site | Google Scholar
  55. C. Bergenfelz, C. Medrek, E. Ekström et al., “Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients,” Journal of Immunology, vol. 188, no. 11, pp. 5448–5458, 2012. View at: Publisher Site | Google Scholar
  56. E.-J. Yeo, L. Cassetta, B.-Z. Qian et al., “Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer,” Cancer Research, vol. 74, no. 11, pp. 2962–2973, 2014. View at: Publisher Site | Google Scholar
  57. J.-H. Lee, G. T. Lee, S. H. Woo et al., “BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages,” Cancer Research, vol. 73, no. 12, pp. 3604–3614, 2013. View at: Publisher Site | Google Scholar
  58. D. P. Nguyen, J. Li, S. S. Yadav, and A. K. Tewari, “Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer,” BJU International, vol. 114, no. 2, pp. 168–176, 2014. View at: Publisher Site | Google Scholar
  59. Z. Yuan, H. J. Mehta, K. Mohammed et al., “TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer,” PLoS ONE, vol. 9, no. 5, Article ID e94241, 2014. View at: Publisher Site | Google Scholar
  60. Z. Yuan, M. A. Syed, D. Panchal et al., “Triggering receptor expressed on myeloid cells 1 (TREM-1)-mediated Bcl-2 induction prolongs macrophage survival,” The Journal of Biological Chemistry, vol. 289, no. 21, pp. 15118–15129, 2014. View at: Publisher Site | Google Scholar
  61. E. P. Chen, N. Markosyan, E. Connolly et al., “Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function,” Carcinogenesis, vol. 35, no. 8, pp. 1788–1797, 2014. View at: Publisher Site | Google Scholar
  62. M. Kujawski, M. Kortylewski, H. Lee, A. Herrmann, H. Kay, and H. Yu, “Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice,” The Journal of Clinical Investigation, vol. 118, no. 10, pp. 3367–3377, 2008. View at: Publisher Site | Google Scholar
  63. C. Rébé, F. Végran, H. Berger, and F. Ghiringhelli, “STAT3 activation,” JAK-STAT, vol. 2, no. 1, Article ID e23010, 2014. View at: Publisher Site | Google Scholar
  64. F. Cheng, H.-W. Wang, A. Cuenca et al., “A critical role for Stat3 signaling in immune tolerance,” Immunity, vol. 19, no. 3, pp. 425–436, 2003. View at: Publisher Site | Google Scholar
  65. M. Kortylewski, M. Kujawski, A. Herrmann et al., “Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy,” Cancer Research, vol. 69, no. 6, pp. 2497–2505, 2009. View at: Publisher Site | Google Scholar
  66. Y. Fujiwara, Y. Komohara, T. Ikeda, and M. Takeya, “Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages,” Cancer Science, vol. 102, no. 1, pp. 206–211, 2011. View at: Publisher Site | Google Scholar
  67. K. Pandima Devi, T. Rajavel, G. L. Russo, M. Daglia, S. F. Nabavi, and S. M. Nabavi, “Molecular targets of omega-3 fatty acids for cancer therapy,” Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 7, pp. 888–895, 2015. View at: Publisher Site | Google Scholar
  68. N. Faragó, L. Z. Fehér, K. Kitajka, U. N. Das, and L. G. Puskás, “MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes,” Lipids in Health and Disease, vol. 10, article 173, 2011. View at: Publisher Site | Google Scholar
  69. S. Serini, R. Ottes Vasconcelos, E. Fasano, and G. Calviello, “Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer,” Expert Opinion on Therapeutic Targets, vol. 20, no. 7, pp. 843–858, 2016. View at: Publisher Site | Google Scholar
  70. E. Mira, L. Carmona-Rodríguez, M. Tardáguila et al., “A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors,” Oncotarget, vol. 4, no. 12, pp. 2288–2301, 2013. View at: Publisher Site | Google Scholar
  71. L. G. Puskás, E. Bereczki, M. Sántha et al., “Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain,” Biochimie, vol. 86, no. 11, pp. 817–824, 2004. View at: Publisher Site | Google Scholar
  72. S. Ostrand-Rosenberg, M. J. Grusby, and V. K. Clements, “Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma,” The Journal of Immunology, vol. 165, no. 11, pp. 6015–6019, 2000. View at: Publisher Site | Google Scholar
  73. P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg, “Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease,” The Journal of Immunology, vol. 174, no. 2, pp. 636–645, 2005. View at: Publisher Site | Google Scholar
  74. T. Lawrence and G. Natoli, “Transcriptional regulation of macrophage polarization: enabling diversity with identity,” Nature Reviews Immunology, vol. 11, no. 11, pp. 750–761, 2011. View at: Publisher Site | Google Scholar
  75. A. Sica and V. Bronte, “Altered macrophage differentiation and immune dysfunction in tumor development,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1155–1166, 2007. View at: Publisher Site | Google Scholar
  76. A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 787–795, 2012. View at: Publisher Site | Google Scholar
  77. A. Saccani, T. Schioppa, C. Porta et al., “p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance,” Cancer Research, vol. 66, no. 23, pp. 11432–11440, 2006. View at: Publisher Site | Google Scholar
  78. C. Porta, M. Rimoldi, G. Raes et al., “Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 35, pp. 14978–14983, 2009. View at: Publisher Site | Google Scholar
  79. C. H. Y. Fong, M. Bebien, A. Didierlaurent et al., “An antiinflammatory role for IKKβ through the inhibition of ‘classical’ macrophage activation,” The Journal of Experimental Medicine, vol. 205, no. 6, pp. 1269–1276, 2008. View at: Publisher Site | Google Scholar
  80. T. Hagemann, T. Lawrence, I. McNeish et al., “'Re-educating' tumor-associated macrophages by targeting NF-κB,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1261–1268, 2008. View at: Publisher Site | Google Scholar
  81. A. Sica, C. Porta, S. Morlacchi et al., “Origin and functions of Tumor-Associated Myeloid Cells (TAMCs),” Cancer Microenvironment, vol. 5, no. 2, pp. 133–149, 2012. View at: Publisher Site | Google Scholar
  82. T. J. Standiford, R. Kuick, U. Bhan, J. Chen, M. Newstead, and V. G. Keshamouni, “TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth,” Oncogene, vol. 30, no. 21, pp. 2475–2484, 2011. View at: Publisher Site | Google Scholar
  83. S. Banerjee, K. Halder, A. Bose et al., “TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages,” Carcinogenesis, vol. 32, no. 12, pp. 1789–1797, 2011. View at: Publisher Site | Google Scholar
  84. E. Riboldi, C. Porta, S. Morlacchi, A. Viola, A. Mantovani, and A. Sica, “Hypoxia-mediated regulation of macrophage functions in pathophysiology,” International Immunology, vol. 25, no. 2, pp. 67–75, 2013. View at: Publisher Site | Google Scholar
  85. C. A. Corzo, T. Condamine, L. Lu et al., “HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment,” Journal of Experimental Medicine, vol. 207, no. 11, pp. 2439–2453, 2010. View at: Publisher Site | Google Scholar
  86. A. L. Doedens, C. Stockmann, M. P. Rubinstein et al., “Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression,” Cancer Research, vol. 70, no. 19, pp. 7465–7475, 2010. View at: Publisher Site | Google Scholar
  87. P. Chaturvedi, D. M. Gilkes, N. Takano, and G. L. Semenza, “Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 20, pp. E2120–E2129, 2014. View at: Publisher Site | Google Scholar
  88. E. P. Cummins, E. Berra, K. M. Comerford et al., “Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18154–18159, 2006. View at: Publisher Site | Google Scholar
  89. J. Rius, M. Guma, C. Schachtrup et al., “NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α,” Nature, vol. 453, no. 7196, pp. 807–811, 2008. View at: Publisher Site | Google Scholar
  90. H. Z. Imtiyaz, E. P. Williams, M. M. Hickey et al., “Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation,” The Journal of Clinical Investigation, vol. 120, no. 8, pp. 2699–2714, 2010. View at: Publisher Site | Google Scholar
  91. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8, pp. 858–864, 2004. View at: Publisher Site | Google Scholar
  92. T. Schioppa, B. Uranchimeg, A. Saccani et al., “Regulation of the chemokine receptor CXCR4 by hypoxia,” Journal of Experimental Medicine, vol. 198, no. 9, pp. 1391–1402, 2003. View at: Publisher Site | Google Scholar
  93. M. Z. Noman, G. Desantis, B. Janji et al., “PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation,” Journal of Experimental Medicine, vol. 211, no. 5, pp. 781–790, 2014. View at: Publisher Site | Google Scholar
  94. D. Laoui, E. Van Overmeire, G. Di Conza et al., “Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population,” Cancer Research, vol. 74, no. 1, pp. 24–30, 2014. View at: Publisher Site | Google Scholar
  95. Y.-J. Jung, J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers, “IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis,” The FASEB Journal, vol. 17, no. 14, pp. 2115–2117, 2003. View at: Google Scholar
  96. W. Chen, T. Ma, X.-N. Shen et al., “Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway,” Cancer Research, vol. 72, no. 6, pp. 1363–1372, 2012. View at: Publisher Site | Google Scholar
  97. Y.-C. Wang, F. He, F. Feng et al., “Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses,” Cancer Research, vol. 70, no. 12, pp. 4840–4849, 2010. View at: Publisher Site | Google Scholar
  98. S. Loges, T. Schmidt, M. Tjwa et al., “Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6,” Blood, vol. 115, no. 11, pp. 2264–2273, 2010. View at: Publisher Site | Google Scholar
  99. O. M. Pello, M. De Pizzol, M. Mirolo et al., “Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology,” Blood, vol. 119, no. 2, pp. 411–421, 2012. View at: Publisher Site | Google Scholar
  100. D. Gurusamy, J. K. Gray, P. Pathrose, R. M. Kulkarni, F. D. Finkleman, and S. E. Waltz, “Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth,” Cancer Research, vol. 73, no. 6, pp. 1752–1763, 2013. View at: Publisher Site | Google Scholar
  101. J. Jin, Y. Xiao, H. Hu et al., “Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages,” Nature Communications, vol. 6, article 5930, 2015. View at: Publisher Site | Google Scholar
  102. J. Zhang, S. Li, L. Li et al., “Exosome and exosomal microRNA: trafficking, sorting, and function,” Genomics, Proteomics and Bioinformatics, vol. 13, no. 1, pp. 17–24, 2015. View at: Publisher Site | Google Scholar
  103. M. K. McDonald, Y. Tian, R. A. Qureshi et al., “Functional significance of macrophage-derived exosomes in inflammation and pain,” Pain, vol. 155, no. 8, pp. 1527–1539, 2014. View at: Publisher Site | Google Scholar
  104. M.-J. Su, H. Aldawsari, and M. Amiji, “Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems,” Scientific Reports, vol. 6, Article ID 30110, 2016. View at: Publisher Site | Google Scholar
  105. K. Essandoh, Y. Li, J. Huo, and G.-C. Fan, “MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response,” Shock, vol. 46, no. 2, pp. 122–131, 2016. View at: Publisher Site | Google Scholar
  106. X.-Q. Wu, Y. Dai, Y. Yang et al., “Emerging role of microRNAs in regulating macrophage activation and polarization in immune response and inflammation,” Immunology, vol. 148, no. 3, pp. 237–248, 2016. View at: Publisher Site | Google Scholar
  107. M. L. Squadrito, M. Etzrodt, M. De Palma, and M. J. Pittet, “MicroRNA-mediated control of macrophages and its implications for cancer,” Trends in Immunology, vol. 34, no. 7, pp. 350–359, 2013. View at: Publisher Site | Google Scholar
  108. K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006. View at: Publisher Site | Google Scholar
  109. M. A. Nahid, K. M. Pauley, M. Satoh, and E. K. L. Chan, “miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity,” The Journal of Biological Chemistry, vol. 284, no. 50, pp. 34590–34599, 2009. View at: Publisher Site | Google Scholar
  110. M. El Gazzar, A. Church, T. F. Liu, and C. E. McCall, “MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming,” Journal of Leukocyte Biology, vol. 90, no. 3, pp. 509–519, 2011. View at: Publisher Site | Google Scholar
  111. M. Etzrodt, V. Cortez-Retamozo, A. Newton et al., “Regulation of monocyte functional heterogeneity by miR-146a and Relb,” Cell Reports, vol. 1, no. 4, pp. 317–324, 2012. View at: Publisher Site | Google Scholar
  112. O. Antal, L. Hackler, J. Shen et al., “Combination of unsaturated fatty acids and ionizing radiation on human glioma cells: cellular, biochemical and gene expression analysis,” Lipids in Health and Disease, vol. 13, no. 1, article no. 142, 2014. View at: Publisher Site | Google Scholar
  113. G. Curtale, M. Mirolo, T. A. Renzi, M. Rossato, F. Bazzoni, and M. Locati, “Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 28, pp. 11499–11504, 2013. View at: Publisher Site | Google Scholar
  114. Y. Zhang, M. Zhang, M. Zhong, Q. Suo, and K. Lv, “Expression profiles of miRNAs in polarized macrophages,” International Journal of Molecular Medicine, vol. 31, no. 4, pp. 797–802, 2013. View at: Publisher Site | Google Scholar
  115. X. Cai, Y. Yin, N. Li et al., “Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155,” Journal of Molecular Cell Biology, vol. 4, no. 5, pp. 341–343, 2012. View at: Publisher Site | Google Scholar
  116. G. Liu and E. Abraham, “MicroRNAs in immune response and macrophage polarization,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. 170–177, 2013. View at: Publisher Site | Google Scholar
  117. P. Wang, J. Hou, L. Lin et al., “Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1,” The Journal of Immunology, vol. 185, no. 10, pp. 6226–6233, 2010. View at: Publisher Site | Google Scholar
  118. M. Nazari-Jahantigh, Y. Wei, H. Noels et al., “MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages,” Journal of Clinical Investigation, vol. 122, no. 11, pp. 4190–4202, 2012. View at: Publisher Site | Google Scholar
  119. R. M. O'Connell, A. A. Chaudhuri, D. S. Rao, and D. Baltimore, “Inositol phosphatase SHIP1 is a primary target of miR-155,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7113–7118, 2009. View at: Publisher Site | Google Scholar
  120. R. T. Martinez-Nunez, F. Louafi, and T. Sanchez-Elsner, “The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor α1 (IL13Rα1),” The Journal of Biological Chemistry, vol. 286, no. 3, pp. 1786–1794, 2011. View at: Publisher Site | Google Scholar
  121. S. Bala, M. Marcos, K. Kodys et al., “Up-regulation of microRNA-155 in macrophages contributes to increased Tumor Necrosis Factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1436–1444, 2011. View at: Publisher Site | Google Scholar
  122. D. Ruffell, F. Mourkioti, A. Gambardella et al., “A CREB-C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 41, pp. 17475–17480, 2009. View at: Publisher Site | Google Scholar
  123. M. He, Z. Xu, T. Ding, D.-M. Kuang, and L. Zheng, “MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPβ,” Cellular and Molecular Immunology, vol. 6, no. 5, pp. 343–352, 2009. View at: Publisher Site | Google Scholar
  124. T. B. Huffaker, R. Hu, M. C. Runtsch et al., “Epistasis between MicroRNAs 155 and 146a during T cell-mediated antitumor immunity,” Cell Reports, vol. 2, no. 6, pp. 1697–1709, 2012. View at: Publisher Site | Google Scholar
  125. E. Zonari, F. Pucci, M. Saini et al., “A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice,” Blood, vol. 122, no. 2, pp. 243–252, 2013. View at: Publisher Site | Google Scholar
  126. N. Valeri, P. Gasparini, M. Fabbri et al., “Modulation of mismatch repair and genomic stability by miR-155,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 15, pp. 6982–6987, 2010. View at: Publisher Site | Google Scholar
  127. E. Tili, J.-J. Michaille, D. Wernicke et al., “Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4908–4913, 2011. View at: Publisher Site | Google Scholar
  128. H. Mathsyaraja, K. Thies, D. A. Taffany et al., “CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth,” Oncogene, vol. 34, no. 28, pp. 3651–3661, 2015. View at: Publisher Site | Google Scholar
  129. Z. Wang, S. Brandt, A. Medeiros et al., “MicroRNA 21 is a homeostatic regulator of macrophage polarization and prevents prostaglandin E2-mediated M2 generation,” PLoS ONE, vol. 10, no. 2, Article ID e0115855, 2015. View at: Publisher Site | Google Scholar
  130. M. L. Squadrito, F. Pucci, L. Magri et al., “MiR-511-3p modulates genetic programs of tumor-associated macrophages,” Cell Reports, vol. 1, no. 2, pp. 141–154, 2012. View at: Publisher Site | Google Scholar
  131. A. A. Chaudhuri, A. Y.-L. So, N. Sinha et al., “MicroRNA-125b potentiates macrophage activation,” Journal of Immunology, vol. 187, no. 10, pp. 5062–5068, 2011. View at: Publisher Site | Google Scholar
  132. S. Banerjee, H. Cui, N. Xie et al., “MiR-125a-5p regulates differential activation of macrophages and inflammation,” Journal of Biological Chemistry, vol. 288, no. 49, pp. 35428–35436, 2013. View at: Publisher Site | Google Scholar
  133. J.-L. Zhao, F. Huang, F. He et al., “Forced activation of notch in macrophages represses tumor growth by upregulating MIR-125a and disabling tumor-associated macrophages,” Cancer Research, vol. 76, no. 6, pp. 1403–1415, 2016. View at: Publisher Site | Google Scholar
  134. Z. Wang, L. Xu, Y. Hu et al., “MiRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer,” Scientific Reports, vol. 6, Article ID 25602, 2016. View at: Publisher Site | Google Scholar
  135. M. Ouimet, H. N. Ediriweera, U. Mahesh Gundra et al., “MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis,” Journal of Clinical Investigation, vol. 125, no. 12, pp. 4334–4348, 2015. View at: Publisher Site | Google Scholar
  136. G. Zhuang, C. Meng, X. Guo et al., “A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation,” Circulation, vol. 125, no. 23, pp. 2892–2903, 2012. View at: Publisher Site | Google Scholar

Copyright © 2017 Gabor J. Szebeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles